- Received at least two prior therapies including bortezomib and an immunomodulatory agent and demonstrated disease progression on or within 60 days of completion of the last therapy. Subjects in Part 2 must also have measurable disease defined as having at least one of the following: Serum M-protein >=0.5 gram/ deciliter (g/dL) (>=5 gram/Liter [g/L]), Urine M-protein >=200 mg/24 hour (h), Serum free light chain (FLC) assay: Involved FLC level >=10 mg/dL (>=100 mg/L) and an abnormal serum free light chain ratio (<0.26 or >1.65), Biopsy proven plasmacytoma (should be measured within 28 days of the Screening Visit)